



## Curriculum Vitae

Personal information Kaisa Sunela

### Work experience

---

1. Employer: Fimea
  - Start date: 082022
  - End date:
  - Position: Clinical assessor, head of section.
  - Activities: Clinical medication studies
  - Country: Finland
2. Employer: Satasairaala
  - Start date: 092018
  - End date: 082019
  - Position: Chief physician (50 %) in oncologic polyclinic
  - Activities:
  - Country: Finland
3. Employer: Tampere University Hospital
  - Start date: 102004
  - End date: 082022
  - Position: specialist in oncology
  - Activities:
  - Country: Finland
4. Employer: Tampere University Hospital
  - Start date: 112000
  - End date: 102004
  - Position: resident in oncology
  - Activities:
  - Country: Finland
5. Employer: Kanta-Häme Central Hospital
  - Start date: 102000
  - End date: 102000
  - Position: resident in psychiatry
  - Activities:
  - Country: Finland
6. Employer: Etelä-Pohjanmaa Central Hospital
  - Start date: 012000
  - End date: 092000
  - Position: resident in internal medicine
  - Activities:
  - Country: Finland
7. Employer: Health center of Ruovesi
  - Start date: 041999
  - End date: 121999
  - Position: Medical doctor in outpatient clinic
  - Activities:
  - Country: Finland

### Education and training

---

- Subject: Tampere University
  - Start date: 11\_2000
  - End date: 10\_2004
  - Qualification: Specialist in oncology
  - Organisation: Medical oncology, specially lymphomas, kidney cancer, urothelial cancer, sarcomas, testicular cancer, clinical oncologic medications
  - Country: Finland
2. Subject: Tampere University
    - Start date: 05\_2004
    - End date: 11\_2013
    - Qualification: PhD
    - Organisation:
    - Country: Finland
  3. Subject: Tampere University
    - Start date: 08\_1993
    - End date: 03\_1999
    - Qualification: Medical doctor
    - Organisation:
    - Country: Finland
  4. Subject: Tampere University
    - Start date: 11\_2020
    - End date: 06\_2023
    - Qualification: eMBA
    - Organisation: Leadership
    - Country: Finland
  5. Subject: Tampere University

- Start date 1\_2025
  - End date 1\_2026
  - Qualification: specialist in health care
  - Country: Finland
6. Subject: Tampere University
- End date: 2\_2024
  - Qualification: Docent title in oncology
  - Country: Finland

## Additional information

### Publications

- Kellokumpu\_Lehtinen PL, Sunela K, et al: A phase I study of an all\_oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. *Clinical Breast Cancer* 7(5): 401\_5, 2006.
- Joensuu H, Sailas L, Alanko T, Sunela K, et al: Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. *Annals of Oncology* 21(5): 968\_73, 2010.
- Sunela KL, Koskinen S, Kellokumpu\_Letinen PL: A phase II study of combination of pegylated interferon alfa\_2a and capecitabine in locally advanced or metastatic renal cell cancer. *Cancer Chemotherapy & Pharmacology* 66(1): 59\_67, 2010.
- Pal SK, Puento J, Heng DYC, Glen H, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Ciuleanu T, Lee JL, Sunela K, et al. Assessing the safety and efficacy of two starting doses of Lenvatinib plus everolimus in patients with renal cell carcinoma: A randomized phase 2 trial. *Eur Urol* 2022; 82:283\_92.
- Sunela K: A typical alcohol seizure? [Tyypillinen alkoholikramppi?, in Finnish]. *Duodecim* 116(4): 381, 383, 2000.
- Sunela KL, et al: Prognostic factors and long\_term survival in renal cell cancer patients. *Scandinavian Journal of Urology & Nephrology* 43(6): 454\_60, 2009.
- Sunela KL, Kataja MJ, Kellokumpu\_Lehtinen PL: Changes in symptoms of renal cell carcinoma over four decades. *BJU Int* 106(5):649\_53, 2010.
- Sunela KL, Kataja MJ, Kellokumpu\_Lehtinen PLI: Influence of body mass index and smoking on the long\_term survival of patients with renal cell cancer. *Clin Genitourin Cancer* 2013; 11(4):458\_64.
- Sunela KL, et al: Development of renal cell carcinoma (RCC) diagnostics and impact on prognosis. *BJU Int* 2014;113:228\_235.
- Virman J, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K, Kellokumpu\_Lehtinen P\_L: Claudins as prognostic factors for renal cell cancer. *Anticancer Res* 2014;34:4181\_88.
- Sunela K, Kellokumpu\_Lehtinen PL: Treatment and prognosis of renal cell cancer [Munuaiissyövän hoito ja ennuste, in Finnish]. *Suomen Lääkärilehti* 2014; 40:2529\_34.
- Virman J, Bono P, Luukkaala T, Sunela K, Kujala P, Kellokumpu\_Lehtinen PL: VEGFR3 and CD31 as prognostic factors in renal cell cancer. *Anticancer Research* 2015;35:921\_8.
- Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Kellokumpu\_Lehtinen PLI: Combined angiogenesis and proliferation markers' expressions as long\_term prognostic factors in renal cell cancer. *Clin Genitourin Cancer* 2016; 14(4):e283\_9.
- Sunela K, Bärlund M: Treatment and prevention of iphosphamide\_induced encephalopathy. [Ifosfamidin aiheuttama enkefalopatia, in Finnish]. *Duodecim* 2016;132:314\_7.
- Lampinen AM, Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Saharinen P, Kellokumpu\_Lehtinen PLI: Novel angiogenesis markers as long\_term prognostic factors in patients with renal cell cancer. *Clin Genitourin Cancer* 2017; 15(1):e15\_24.
- Kaartinen I, Sunela K, Alanko J, Hukkinen K, Karjalainen\_Lindsberg ML, Svarvar C: Breast implant\_associated anaplastic large cell lymphoma – from diagnosis to treatment. *Eur J Surg Oncol* 2017; 43:1385\_92.
- Vänskä M, Huttunen R, Sunela K, Rimpiläinen J, Karlsson S, Keskinen L, Pohjolainen V, Vornanen M, Kalliomiäki J: [Are you familiar with hemophagocytosis?, in Finnish] *Duodecim* 2018;134:79\_83.
- Sunela K, Leppä S, Kuittinen O, Tinkanen H, Tuohinen S, Schmitt F, Korkeila E. Late complications of lymphoma treatment, prevention and follow\_up. [in Finnish] *Duodecim* 2020, 136:2373\_81.
- Rajamäki A, Sunela K, Prusila REI, Kuusisto MEL, Mercadal S, Selander T, Kuitunen H, Pollari M, Jantunen E, Nystrand I, Sancho J\_M, Sorigue M, Kuittinen O. Female patients with follicular lymphoma have a better prognosis if primary remission last over 24 months. *Leukemia & Lymphoma* 2021; 62(7):1639\_47
- Sunela K, Mäenpää H, Tolonen T, Syvänen K, Boström P. Treatment of testicular cancer, [in Finnish Kivessyövän hoito]. *Duodecim* 2021; 137:477\_86.
- Sunela K, Aho S, Tiainen K. Incurable cancer in young adult \_ holistic grip will go further. [in Finnish: Nuoren aikuisen parantumaton syöpä \_ kokonaisvaltainen hoito\_ote kantaa pitkälle] *Duodecim* 2022; 138:501\_6.
- Rajamäki A, Hujo M, Sund R, Prusila REI, Kuusisto MEL, Kuitunen H, Jantunen E, Mercadal S, Sorigue M, Sancho J\_M, Sunela K, Kuittinen O: Mortality among patients with low\_grade follicular lymphoma: A binational retrospective analysis. *Cancer* 2022; 128(13):2474\_2482.
- Rajamäki A, Kuitunen H, Sorigue M, Kokkonen S\_M, Kuittinen O, Sunela K. FDG\_PET/Ct\_guided rebiopsy may find clinically unsuspected transformation of follicular lymphoma. *Cancer Medicine* 2022; DOI: 10.1002/cam4.4924.

Harmanen M, Hujo M, Sund R, Sorigue M, Khan M, Prusila R, Klaavuniemi T, Kari E, Jantunen E, **Sunela K**, Rajamäki A, Alanne E, Kuitunen H, Sancho JM, Jukkola A, Rönkä A, Kuittinen O. Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020. *Br J Haematol* 2022; 00:1-11.

Bergerot C, Rha SY, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lee JL, **Sunela K**, Ciuleanu T, Heng D, Glen H,

Wang J, Bennett L, Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of Lenvatinib in combination with everolimus for previously treated renal cell carcinoma. *Oncologist* 2023; 28:59-71.

Porta C, ..., **Sunela K**, ..., Santoni M. Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. *Minerva Urol Nephrol* 2023; 75(4):460-470.

Jokimäki A, Hietala H, Lemma J, Karhapää H, Rintala A, Kaikkonen J-P, **Sunela K**, ..., Outi Kuittinen. Previous radiotherapy improves treatment responses and causes a trend towards longer time to progression among patients with immune checkpoint inhibitor-related adverse events. *Cancer Immunology, Immunotherapy*. <https://link.springer.com/article/10.1007/s00262-023-03494-4>;

Santoni M, ..., **Sunela K**, ..., Porta C. Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria treated by immune-oncology combinations: Differential effectiveness by risk group? *Eur Urol Oncol* 2023 Jul 20; S2588-9311(23)00145-1.

Rajamäki A, Hujo M, Prusila R, Kuusisto-Jauhiainen M, Kuitunen H, Jantunen E, Mercadal S, Sorigue M, Sancho JM, **Sunela K**, Kuittinen O. Estimating the lifetime treatment burden of patients with follicular lymphoma: A retrospective study using real-world multicenter data. *JCO Clin Cancer Inform* 2023; 7:e2300067.

Kuitunen H, Puhakka I, Rönkä A, Selander T, Jakala P, Arkko U-M, Klaavuniemi T, **Sunela K**, Rajamäki A, Kuittinen O. Rapid diagnosis and treatment has a crucial role in the prognosis of primary central nervous system lymphoma, PCNSL. *Br J Haem* 2023, 203(2):e78-81.

Airo A, **Sunela K**. Late complications and survival of soft tissue sarcoma patients after adjuvant chemotherapy - a single tertiary centre experience. *Acta Oncologica* 2023;62:9, 1152-56.

Kuitunen H, **Sunela K**, Sipilä K, Vääräsmäki M, Vasala K, Kuittinen O. Raskauden aikana ilmenevä lymfooma on hoidettavissa (in Finnish). *Lääkärilehti* 2023; 78:e37453/2023; 41:1598-1602.

Harmanen M, Sorigue M, Khan M, Prusila R, Kari E, Alanne E, Rajamäki A, **Sunela K**, Jukkola A, Jantunen E, Sancho JM, Ketola S, Kuitunen H, Selander T, Rönkä A, Kuittinen O. Real-World Data: MCL2 Protocol demonstrates excellent results among patients with mantle cell lymphoma not fulfilling the original trial inclusion criteria. *HemaSphere* 2023; 7:10(e954).

Harmanen M, Sorigue M, Khan M, Prusila R, Klaavuniemi T, Kari E, Jantunen E, **Sunela K**, Rajamäki A, Alanne E, Kuitunen H, Jukkola A, Sancho JM, Kuittinen O, Rönkä A. Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis. *Eur J Haematol* 2024; 1-9.

Ciccarese C, ..., **Sunela K**, ..., Santoni M. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study). *Int J Cancer* 2024; 1-11.

**Sunela K**, Grönholm E, Utriainen M. Immunokonjugaatit syövän hoidossa (in Finnish). *Duodecim* 2024; 140:1805-13.

Puhakka IK, **Sunela K**, Rönkä AL, Rajamäki AM, Arkko UM, Klaavuniemi TUM, Kuusisto MEL, Jäkälä PA, Selander TA, Kuitunen HK, Kantanen AM, Kuittinen OM. Defining MRI-based follow-up protocol for primary central nervous system lymphoma. *Ann Hematol* 2025; 104:627-34.

Mishra S, ..., **Sunela K**, ..., Reunanen J. Gut microbiome-derived bacterial extracellular vesicles in patients with solid tumours. *J Advanced Res* 2025, 68:375-86.

Harmanen M, Hujo M, Sund M, Sorigue M, Khan M, Prusila R, Klaavuniemi T, Kari E, Jantunen E, **Sunela K**, Rajamäki A, Alanne E, Kuitunen H, Sancho JM, Jukkola A, Rönkä A, Kuittinen O. Lifetime treatment trajectories of mantle cell lymphoma: simulation based analysis of 20 years of real-world data. *Hematol Oncol* 2025; 43:e70024.

Pellonperä E, Puhakka I, Kuitunen H, Rönkä A, **Sunela K**, Kuusisto MEL, Klaavuniemi T, Jäkälä P, Rajamäki A, Arkko U-M, Kuittinen O. Favourable outcome of relapsed PCNSL among transplant eligible patients. *Eur J Haematol* 2025; 114:840-846.

Leppä S, ..., **Sunela K**, ..., Holte H. Biomarker-adapted treatment in high-risk large B-cell lymphoma. *Hemasphere* 2025; 9:e70139.

Massari F, Mollica V, Kopp RM, Grande E, ...**Sunela K**,...Santoni M. Immune-based combinations in intermediate-/poor-risk patients with non-clear cell renal carcinoma: results from the ARON-1 study. Eur Urol 2025; <https://doi.org/10.1016/j.euf.2025.05.020>

Aguzzi C, ..., **Sunela K**, ..., Santoni M. mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1a). Biochemistry and Biophysics Reports 2025; 43:102162.

Tuomarila M, Poikonen-Saksela P, Kondylakis H, Mattson J, Auvinen P, Jukkola A, Kalashnikov I, Koivunen J, Kääriäinen O-S, **Sunela K**, Utriainen M, Vihinen P, Leppä S, Karihtala P. Impact of the Covid-19 pandemic on the quality of life of early breast cancer patients undergoing adjuvant chemotherapy – an observational, multicenter study. Acta Oncol 2025; 64:1381-90.

Lipponen O, Pöyhönen A, Kotsar A, Veitonmäki T, Teuvo LJ Tammela, **Sunela K**, Murtola TJ. Renal cancer survival an duse of 5alpha-reductase inhibitors or androgen deprivation therapy. BMC Urology 2025;25:243.

Santoni M, Roviell G, Grande E, ...**Sunela K**, ...Massari F. Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). Cancer Immunology, Immunotherapy 2025; 74:225.

Molina-Cerrillo J, Rovielle G, ...**Sunela K**, ...Santoni M. Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study). Int J Cancer 2025:1-10.

Tokola S, Marin K, Kuusisto MEL, Kuitunen H, Pollari M, Jyrkkiö S, Suominen M, Vuolukka K, Harmanen M, **Sunela K**, Rönkä A, Selander T, Aromaa-Häyhä A, Ylhäinen S, Klaavuniemi T, Hakalahti A, Kuitinen O. Prolonged time from symptoms to diagnosis is associated with an inferior progression-free survival in diffuse large B-cell lymphoma. Cancer Med 2025; 14:e71409.

Kankkunen E, **Sunela K**, Makkonen T, Jalkanen K, Mattila KE. Antibiotic treatment indicates shorter survival in patients with immunotherapy for metastatic kidney cancer. Acta Oncologica 2026; vol 65, 83-89.

**Sunela K**, Palomäki J. Vastuullisuus – kestäväään kehitykseen kliinisissä lääketutkimuksissa ja niiden suunnittelussa (in Finnish). Duodecim 2026; 142:3291-8.

#### Projects

Have been involved until 15.7.2022 in multiple clinical trials.

#### Memberships

Scandinavian Sarcoma group, board member until 5/2025.

#### Other Relevant Information